Harmonisation of the HLA tests for the diagnosis of coeliac disease: experiences from the Czech external proficiency testing program
- PMID: 39315311
- PMCID: PMC11416978
- DOI: 10.3389/fgene.2024.1441769
Harmonisation of the HLA tests for the diagnosis of coeliac disease: experiences from the Czech external proficiency testing program
Abstract
Coeliac disease (CD) is an autoimmune disorder caused by the ingestion of gluten-containing grains. One of the prerequisites for the development of the disease is the presence of specific combinations of HLA alleles at the DQA1 and DQB1 loci. The HLA test is a supportive diagnostic test. In the Czech Republic, approximately 3,500 HLA tests for CD diagnosis are performed annually in almost three dozen laboratories. The HLA Department of the Institute of Haematology and Blood Transfusion in Prague has been offering the EPT "Detection of HLA Alleles Associated with Diseases" for more than 10 years. The results are evaluated in terms of the correct determination of predisposing alleles/allelic groups and clinical interpretation. Every year, we notice some problems with the detection of CD-associated alleles and the interpretation of results. Annual workshops are part of this EPT, and they also include recommendations for the interpretation of results. This interpretation is evolving based on the current knowledge in the field. The current recommendation for interpretation was adopted in 2023, dividing HLA-DQA1/DQB1 genotypes into three categories: 1) detected HLA genotype is associated with predisposition to coeliac disease; 2) coeliac disease could not be excluded based on the detected HLA genotype; 3) coeliac disease could be excluded with high probability based on the detected HLA genotype. The quality of examination is increasing but still needs improvement. Correct results and accurate interpretation can inform clinicians' decisions about the diagnosis of coeliac disease in appropriate patients.
Keywords: HLA; coeliac disease; disease association; external proficiency testing; genetic susceptibility.
Copyright © 2024 Vrana, Tajtlova and Mrazek.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
UK NEQAS and BSHI guideline: Laboratory testing and clinical interpretation of HLA genotyping results supporting the diagnosis of coeliac disease.Int J Immunogenet. 2024 Jan;51 Suppl 1:3-20. doi: 10.1111/iji.12649. Epub 2023 Dec 28. Int J Immunogenet. 2024. PMID: 38153308
-
High rates of variation in HLA-DQ2/DQ8 testing for coeliac disease: results from an RCPAQAP pilot program.J Clin Pathol. 2018 Oct;71(10):900-905. doi: 10.1136/jclinpath-2018-205209. Epub 2018 May 15. J Clin Pathol. 2018. PMID: 29764931
-
HLA-DQA1*05-DQB1*0201 positivity predisposes to coeliac disease in Czech diabetic children.Acta Paediatr. 2000 Dec;89(12):1426-30. doi: 10.1080/080352500456589. Acta Paediatr. 2000. PMID: 11195230
-
Population genetics and external proficiency testing for HLA disease associations.Front Genet. 2023 Oct 23;14:1268705. doi: 10.3389/fgene.2023.1268705. eCollection 2023. Front Genet. 2023. PMID: 37937194 Free PMC article. Review.
-
Carrier frequency of HLA-DQB1*02 allele in patients affected with celiac disease: A systematic review assessing the potential rationale of a targeted allelic genotyping as a first-line screening.World J Gastroenterol. 2020 Mar 28;26(12):1365-1381. doi: 10.3748/wjg.v26.i12.1365. World J Gastroenterol. 2020. PMID: 32256023 Free PMC article.
References
-
- Al-Toma A., Volta U., Auricchio R., Castillejo G., Sanders D. S., Cellier C., et al. (2019). European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur. Gastroenterol. J. 7 (5), 583–613. Epub 2019 Apr 13. PMID: 31210940; PMCID: PMC6545713. 10.1177/2050640619844125 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials